Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (351-360 of 427) with videos related to

Pageof 43
Sort By:
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Leukemia|January 20, 2024
Real-world analysis of teclistamab in 123 RRMM patients from GermanyC Riedhammer, F Bassermann, B Besemer, et al.
Cancer|March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelomaFredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Leukemia|March 5, 2020
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Leukemia|August 9, 2014
Role of Growth arrest-specific gene 6-Mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Pageof 43

Showing results (351-360 of 427) with videos related to

Sort By:
Pageof 43
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Hemasphere|November 21, 2024
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trialElias K Mai, Axel Nogai, Henk M Lokhorst, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Leukemia|January 20, 2024
Real-world analysis of teclistamab in 123 RRMM patients from GermanyC Riedhammer, F Bassermann, B Besemer, et al.
Cancer|March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelomaFredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Leukemia|March 5, 2020
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Leukemia|August 9, 2014
Role of Growth arrest-specific gene 6-Mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
Pageof 43